A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study will be a multicenter, prospective, open label, one-arm study intended to assess
the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.
In patients with one primary superficial or nodular basal cell carcinoma lesion with a
diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities
(not including the hands), with well-defined borders and no previous radiation therapy.